Strategies to manage hepatitis C virus infection disease burden - volume 3.

Strategies to manage hepatitis C virus infection disease burden - volume 3.

Alfaleh, F Z;Nugrahini, N;Matičič, M;Tolmane, I;Alzaabi, M;Hajarizadeh, B;Valantinas, J;Kim, D Y;Hunyady, B;Abaalkhail, F;Abbas, Z;Abdou, A;Abourached, A;Al Braiki, F;Al Hosani, F;Al Jaberi, K;Al Khatry, M;Al Mulla, M A;Al Quraishi, H;Al Rifai, A;Al Serkal, Y;Alam, A;Alashgar, H I;Alavian, S M;Alawadhi, S;Al-Dabal, L;Aldins, P;Alghamdi, A S;Al-Hakeem, R;Aljumah, A A;Almessabi, A;Alqutub, A N;Alswat, K A;Altraif, I;Andrea, N;Assiri, A M;Babatin, M A;Baqir, A;Barakat, M T;Bergmann, O M;Bizri, A R;Chaudhry, A;Choi, M S;Diab, T;Djauzi, S;El Hassan, E S;El Khoury, S;Estes, C;Fakhry, S;Farooqi, J I;Fridjonsdottir, H;Gani, R A;Ghafoor Khan, A;Gheorghe, L;Goldis, A;Gottfredsson, M;Gregorcic, S;Gunter, J;Hamid, S;Han, K H;Hasan, I;Hashim, A;Horvath, G;Husni, R;Jafri, W;Jeruma, A;Jonasson, J G;Karlsdottir, B;Kim, Y S;Koutoubi, Z;Lesmana, L A;Liakina, V;Lim, Y S;Löve, A;Maimets, M;Makara, M;Malekzadeh, R;Memon, M S;Merat, S;Mokhbat, J E;Mourad, F H;Muljono, D H;Nawaz, A;Olafsson, S;Priohutomo, S;Qureshi, H;Rassam, P;Razavi, H;Razavi-Shearer, D;Razavi-Shearer, K;Rozentale, B;Sadik, M;Saeed, K;Salamat, A;Salupere, R;Sanai, F M;Sanityoso Sulaiman, A;Sayegh, R A;Schmelzer, J D;Sharara, A I;Sibley, A;Siddiq, M;Siddiqui, A M;Sigmundsdottir, G;Sigurdardottir, B;Speiciene, D;Sulaiman, A;Sultan, M A;Taha, M;Tanaka, J;Tarifi, H;Tayyab, G;Ud Din, M;Umar, M;Videčnik-Zorman, J;Yaghi, C;Yunihastuti, E;Yusuf, M A;Zuberi, B F;Blach, S;
journal of viral hepatitis 2015 Vol. 22 Suppl 4 pp. 42-65
378
alfaleh2015strategiesjournal

Abstract

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).

Citation

ID: 55096
Ref Key: alfaleh2015strategiesjournal
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
55096
Unique Identifier:
10.1111/jvh.12474
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet